TY - JOUR
T1 - ACR–ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy
AU - Harkenrider, Matthew M.
AU - Albuquerque, Kevin
AU - Brown, Derek
AU - Kamrava, Mitchell
AU - King, Martin
AU - Mourtada, Firas
AU - Orio, Peter
AU - Patel, Rakesh
AU - Price, Michael
AU - Rassiah, Prema
AU - Solanki, Abhishek A.
AU - Small, William
AU - Schechter, Naomi R.
N1 - Publisher Copyright:
© 2021
PY - 2021/11/1
Y1 - 2021/11/1
N2 - purpose: This practice parameter aims to detail the processes, qualifications of personnel, patient selection, equipment, patient and personnel safety, documentation, and quality control and improvement necessary for an HDR brachytherapy program. Methods and Materials: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Society for Radiation Oncology (ASTRO). Results: Brachytherapy is a radiotherapeutic modality in which radionuclide or electronic sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application. Brachytherapy alone or combined with external beam radiotherapy plays an important role in the management and treatment of patients with cancer. High-dose-rate (HDR) brachytherapy uses radionuclides, such as iridium-192, at dose rates of ≥12 Gy/hr to a designated target point or volume, and it is an important treatment for a variety of malignant and benign conditions. Its use allows for application of high doses of radiation to defined target volumes with relative sparing of adjacent critical structures. Conclusions: HDR brachytherapy requires detailed attention to personnel, equipment, patient and personnel safety, and continuing staff education. Coordination between the radiation oncologist and treatment planning staff and effective quality assurance procedures are important components of successful HDR brachytherapy programs.
AB - purpose: This practice parameter aims to detail the processes, qualifications of personnel, patient selection, equipment, patient and personnel safety, documentation, and quality control and improvement necessary for an HDR brachytherapy program. Methods and Materials: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Society for Radiation Oncology (ASTRO). Results: Brachytherapy is a radiotherapeutic modality in which radionuclide or electronic sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application. Brachytherapy alone or combined with external beam radiotherapy plays an important role in the management and treatment of patients with cancer. High-dose-rate (HDR) brachytherapy uses radionuclides, such as iridium-192, at dose rates of ≥12 Gy/hr to a designated target point or volume, and it is an important treatment for a variety of malignant and benign conditions. Its use allows for application of high doses of radiation to defined target volumes with relative sparing of adjacent critical structures. Conclusions: HDR brachytherapy requires detailed attention to personnel, equipment, patient and personnel safety, and continuing staff education. Coordination between the radiation oncologist and treatment planning staff and effective quality assurance procedures are important components of successful HDR brachytherapy programs.
KW - Brachytherapy
KW - HDR brachytherapy
KW - High-dose-rate brachytherapy
KW - Radiation oncology
KW - Radionuclides
UR - http://www.scopus.com/inward/record.url?scp=85115933999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115933999&partnerID=8YFLogxK
U2 - 10.1016/j.brachy.2021.08.009
DO - 10.1016/j.brachy.2021.08.009
M3 - Article
C2 - 34588143
AN - SCOPUS:85115933999
SN - 1538-4721
VL - 20
SP - 1071
EP - 1082
JO - Brachytherapy
JF - Brachytherapy
IS - 6
ER -